AGILENT TECHNOLOGIES, INC.
AAPI behind this page
A FY 2025 request
Playground key active
/api/financials?ticker=A&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 6,948 | 6,510 | +6.7% |
Show Product Lines breakouts |
|||
| Instrumentation | 2,427 | 2,354 | +3.1% |
| Non-Instrumentation and Other | 4,521 | 4,156 | +8.8% |
| Product | 4,944 | 4,672 | +5.8% |
| Service Other | 2,004 | 1,838 | +9.0% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 2,908 | 2,747 | +5.9% |
| Agilent CrossLab · Americas | 1,095 | 1,048 | +4.5% |
| Agilent CrossLab · Asia Pacific | 1,002 | 958 | +4.6% |
| Agilent CrossLab · Europe | 811 | 741 | +9.4% |
| Agilent CrossLab · Operating Segments | 2,908 | 2,747 | +5.9% |
| Applied Markets | 1,314 | 1,297 | +1.3% |
| Applied Markets · Americas | 374 | 368 | +1.6% |
| Applied Markets · Asia Pacific | 614 | 623 | -1.4% |
| Applied Markets · Europe | 326 | 306 | +6.5% |
| Applied Markets · Operating Segments | 1,314 | 1,297 | +1.3% |
| Life Sciences and Diagnostics Markets | 2,726 | 2,466 | +10.5% |
| Life Sciences and Diagnostics Markets · Americas | 1,337 | 1,157 | +15.6% |
| Life Sciences and Diagnostics Markets · Asia Pacific | 603 | 586 | +2.9% |
| Life Sciences and Diagnostics Markets · Europe | 786 | 723 | +8.7% |
| Life Sciences and Diagnostics Markets · Operating Segments | 2,726 | 2,466 | +10.5% |
Show Geography breakouts |
|||
| Americas | 2,806 | 2,573 | +9.1% |
| Asia Pacific | 2,219 | 2,167 | +2.4% |
| CN | 1,224 | 1,217 | +0.6% |
| Europe | 1,923 | 1,770 | +8.6% |
| Rest Of World | 3,382 | 3,047 | +11.0% |
| US | 2,342 | 2,246 | +4.3% |
Show End Markets [Axis] breakouts |
|||
| Academia and Government Market | 540 | 567 | -4.8% |
| Chemical and Advanced Materials Market | 1,561 | 1,495 | +4.4% |
| Diagnostics and Clinical Market | 1,029 | 964 | +6.7% |
| Environmental and Forensics Market | 674 | 650 | +3.7% |
| Food Market | 637 | 592 | +7.6% |
| Pharmaceutical and Biopharmaceutical Market | 2,507 | 2,242 | +11.8% |
| Cost of Revenue | 3,305 | 2,975 | +11.1% |
Show Product Lines breakouts |
|||
| Product | 2,237 | 2,024 | +10.5% |
| Service Other | 1,068 | 951 | +12.3% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 1,297 | 1,185 | +9.5% |
| Applied Markets · Operating Segments | 599 | 580 | +3.3% |
| Life Sciences and Diagnostics Markets · Operating Segments | 1,301 | 1,121 | +16.1% |
| Research & Development | 455 | 479 | -5.0% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 106 | 105 | +1.0% |
| Applied Markets · Operating Segments | 93 | 94 | -1.1% |
| Life Sciences and Diagnostics Markets · Operating Segments | 248 | 250 | -0.8% |
| Selling, General & Administrative | 1,709 | 1,568 | +9.0% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 559 | 532 | +5.1% |
| Applied Markets · Operating Segments | 321 | 311 | +3.2% |
| Life Sciences and Diagnostics Markets · Operating Segments | 641 | 611 | +4.9% |
| Total Costs & Expenses | 5,469 | 5,022 | +8.9% |
| Operating Income | 1,479 | 1,488 | -0.6% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 946 | 925 | +2.3% |
| Applied Markets · Operating Segments | 301 | 312 | -3.5% |
| Life Sciences and Diagnostics Markets · Operating Segments | 536 | 484 | +10.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,783 | 1,721 | +3.6% |
| Interest Income | 62 | 80 | -22.5% |
| Interest Expense | -112 | -96 | -16.7% |
| Other Non-Operating Income (Expense) | 6 | 49 | -87.8% |
| Income Before Taxes | 1,435 | 1,521 | -5.7% |
| Income Tax Expense (Benefit) | 132 | 232 | -43.1% |
Show Reasonably Possible Significant Change In Unrecognized Tax Benefits By Item breakouts |
|||
| Tax Interest and Penalties | -9 | 1 | -1000.0% |
| Net Income | 1,303 | 1,289 | +1.1% |
Show Equity Components breakouts |
|||
| Parent | 1,303 | 1,289 | +1.1% |
| Retained Earnings | 1,303 | 1,289 | +1.1% |
| EPS (Basic) | 4.59 | 4.44 | +3.4% |
| EPS (Diluted) | 4.57 | 4.43 | +3.2% |
| Wtd Avg Shares (Basic) | 284 | 290 | -2.1% |
| Wtd Avg Shares (Diluted) | 285 | 291 | -2.1% |
| Operating Expenses (FY) | — | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 304 | 233 | +30.5% |
| Comprehensive Income | 1,382 | 1,311 | +5.4% |
Show Equity Components breakouts |
|||
| Parent | 1,382 | 1,311 | +5.4% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | -1 | -7 | +85.7% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,789 | 1,329 | +34.6% |
Show Geography breakouts |
|||
| Non Us | 1,656 | — | — |
| Accounts Receivable | 1,487 | 1,324 | +12.3% |
| Inventory | 1,025 | 972 | +5.5% |
| Other Assets Current | 293 | 334 | -12.3% |
| Total Current Assets | 4,594 | 3,959 | +16.0% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,023 | 1,778 | +13.8% |
| Goodwill | 4,473 | 4,477 | -0.1% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 1,168 | 1,168 | 0.0% |
| Applied Markets | 309 | 309 | 0.0% |
| Life Sciences and Diagnostics Markets | 2,996 | 3,000 | -0.1% |
| Long Term Investments | 133 | 175 | -24.0% |
| Other Non-Current Assets | 1,059 | 910 | +16.4% |
| Total Assets | 12,727 | 11,846 | +7.4% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Not Primary Beneficiary | 44 | 79 | -44.3% |
| Operating Lease Right-of-Use Assets | 183 | 177 | +3.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 445 | 547 | -18.6% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 160 | 184 | -13.0% |
| Developed Technology Rights | 249 | 315 | -21.0% |
| Order Or Production Backlog | 7 | 9 | -22.2% |
| Third-Party Technology and Licenses | 11 | 14 | -21.4% |
| Trademarks | 18 | 25 | -28.0% |
| Current Liabilities | |||
| Accounts Payable | 570 | 540 | +5.6% |
| Employee Related Liabilities Current | 443 | 368 | +20.4% |
| Deferred Revenue | 624 | 544 | +14.7% |
| Short Term Borrowings | 304 | 45 | +575.6% |
Show Debt Instrument breakouts |
|||
| Other Loans | 4 | 5 | -20.0% |
| Other Liabilities Current | 406 | 398 | +2.0% |
| Total Current Liabilities | 2,347 | 1,895 | +23.9% |
| Long-Term Debt | 3,050 | 3,345 | -8.8% |
Show Debt Instrument breakouts |
|||
| Other Loans | 20 | 19 | +5.3% |
| Senior Notes 2027 · Senior Notes | 597 | 596 | +0.2% |
| Senior Notes 2029 · Senior Notes | 497 | 496 | +0.2% |
| Senior Notes 2030 · Senior Notes | 498 | 497 | +0.2% |
| Senior Notes 2031 · Senior Notes | 845 | 845 | 0.0% |
| Senior Notes 2034 · Senior Notes | 593 | 593 | 0.0% |
Show Long-Term Debt Type breakouts |
|||
| Senior Notes | 3,030 | 3,326 | -8.9% |
| Current Portion of Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| Senior Notes 2026 · Senior Notes | 300 | — | — |
| Non-Current Liabilities | |||
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 126 | 130 | -3.1% |
| Other Non-Current Liabilities | 463 | 578 | -19.9% |
| Total Liabilities | 5,986 | 5,948 | +0.6% |
| Operating Lease Liabilities | 145 | 142 | +2.1% |
| Accrued Income Taxes Noncurrent | -28 | -115 | +75.7% |
| Stockholders' Equity | |||
| Common Stock | 3 | 3 | 0.0% |
| Additional Paid-In Capital | 5,575 | 5,450 | +2.3% |
| Retained Earnings | 1,389 | 750 | +85.2% |
| Accumulated Other Comprehensive Income | -226 | -305 | +25.9% |
| Total Stockholders' Equity | 6,741 | 5,898 | +14.3% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -226 | -305 | +25.9% |
| Additional Paid In Capital | 5,575 | 5,450 | +2.3% |
| Common Stock | 3 | 3 | 0.0% |
| Parent | 6,741 | 5,898 | +14.3% |
| Retained Earnings | 1,389 | 750 | +85.2% |
| Total Liabilities & Equity | 12,727 | 11,846 | +7.4% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 288 | 257 | +12.1% |
| Stock-Based Compensation | 128 | 129 | -0.8% |
| Deferred Income Taxes | -130 | -64 | -103.1% |
| Inventory Write Down | 45 | 45 | 0.0% |
| Equity Securities Fv Ni Gain Loss | -36 | 6 | -700.0% |
| Impairment Of Intangible Assets Excluding Goodwill | 15 | 19 | -21.1% |
| Other Non-Cash Items | 5 | -1 | +600.0% |
| Change in Accounts Receivable | -149 | 7 | -2228.6% |
| Change in Inventory | -97 | 34 | -385.3% |
| Change in Accounts Payable | 16 | 103 | -84.5% |
| Increase Decrease In Employee Related Liabilities | 69 | -12 | +675.0% |
| Increase Decrease In Other Operating Capital Net | 30 | -49 | +161.2% |
| Net Cash from Operations | 1,559 | 1,751 | -11.0% |
| Change in Deferred Revenue | 564 | 469 | +20.3% |
| Investing Activities | |||
| Capital Expenditures | -407 | -378 | -7.7% |
| Proceeds From Sale Of Equity Securities Fv Ni | 8 | — | — |
| Proceeds From Sale Of Notes Receivable | 2 | — | — |
| Payments To Acquire Notes Receivable | -1 | -13 | +92.3% |
| Payments To Acquire Businesses Net Of Cash Acquired | 4 | -862 | +100.5% |
| Net Cash from Investing | -394 | -1,258 | +68.7% |
| Financing Activities | |||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 72 | 77 | -6.5% |
| Tax Withholding for Share Compensation | 29 | 30 | -3.3% |
| Share Repurchases | -425 | -1,150 | +63.0% |
| Payment Of Excise Taxes Related To Repurchases Of Common Stock | -10 | -3 | -233.3% |
| Payments Of Dividends Common Stock | -282 | -274 | -2.9% |
| Proceeds From Issuance Of Long Term Debt | 4 | 1,197 | -99.7% |
| Repayments Of Long Term Debt | -3 | -600 | +99.5% |
| Proceeds From Repayments Of Short Term Debt | -42 | 40 | -205.0% |
| Net Cash from Financing | -715 | -752 | +4.9% |
| Supplemental | |||
| Income Taxes Paid | 318 | 314 | +1.3% |
| Interest Paid | 101 | 80 | +26.2% |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | 11 | 9 | +22.2% |
| Share Repurchase Program Excise Tax Payable | 3 | 10 | -70.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 9 | -2 | +550.0% |
| Net Change in Cash | 459 | -261 | +275.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,791 | 1,332 | +34.5% |
Values in millions USD. Source: SEC EDGAR 10-K filing.